Skip to content
montabiosciences.commontabiosciences.com
  • Home
  • About us
    • Company History
    • Management
    • Board of Directors
    • Founders
  • Technology
    • Todays Challenges
    • Cancer Treatment
    • Cancer Immunotherapy
    • Development
    • References
  • News
  • Contact Us
News

Meet us at BioEquity in Praha in early May

MonTa Biosciences will be joining the BioEquity meeting in Praha in early May to build relationship with our network and with the investor community

MonTa Biosciences Initiates Expansion Phase with Systemic TLR7 Agonist MBS8 in Checkpoint-Resistant Melanoma Amid Renewed Momentum in the TLR7 Field
First patient treated in Cutaneous Melanoma patient with secondary resistance

MonTa Biosciences ApS

Diplomvej 381
2800 Kgs. Lyngby
Denmark

VAT nr. 36697016

Privacy statement
MonTa Biosciences - Cancer Therapeutics of Tomorrow
  • Home
  • About us
    • Company History
    • Management
    • Board of Directors
    • Founders
  • Technology
    • Todays Challenges
    • Cancer Treatment
    • Cancer Immunotherapy
    • Development
    • References
  • News
  • Contact Us